By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Oculis 

Grandagardur 16

Reykjavik    IS-101  Iceland
Phone: 354-546-4440 Fax: 354-519-7996


SEARCH JOBS

Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye.

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

YEAR FOUNDED:

2003

LEADERSHIP:

Founders: Einar Stefansson, MD, PhD and Thorsteinn Loftsson, PhD

CEO: Pall Ragnar Johnnesson

CCO: (Regulatory and Clinical) Gudrun Marta Asgrimsdottir, MSc

CSO: Thorsteinn Loftsson, PhD

JOBS:

Please click here for.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW AMGEN:




Key Statistics


Email: info@oculispharma.com
Ownership: Private

Web Site: Oculis
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->